Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining a janus kinase (JAK)‐inhibitor with ibrutinib because JAK‐mediated cytokine‐signals support CLL ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Spaner, David E., McCaw, Lindsay, Wang, Guizhei, Tsui, Hubert, Shi, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488147/
https://www.ncbi.nlm.nih.gov/pubmed/30843659
http://dx.doi.org/10.1002/cam4.2042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488147/
https://www.ncbi.nlm.nih.gov/pubmed/30843659
http://dx.doi.org/10.1002/cam4.2042

Ejemplares similares